# Dr. Neil Sankar, MD, MPH

*Medical Oncologist | C-Suite Executive | Drug Development Leader*

Email: neilshankar@gmail.com Location: United States

## Professional Summary

Accomplished physician and Medical Oncologist with over 22 years of global experience in life sciences, biotechnology, and pharmaceutical drug development. Trained at prestigious institutions including the National Cancer Institute (NCI) and with a Master of Public Health from Queensland, Australia. Proven leadership in clinical strategy, regulatory engagement, and medical oversight, with a successful track record in two FDA-approved NDAs. Expertise spans oncology, hematology, immunology, infectious diseases, and cutting-edge therapeutic platforms including CAR-T, ADCs, oncolytic viruses, and NK cell therapies.

## Education

MD (Medical Oncology) - India and University of the West Indies

MPH (Public Health) - Queensland, Australia

Oncology Fellowship - National Cancer Institute (NCI), Bethesda, NIH/HHS

- Focus: CTEP-sponsored clinical trials

## Professional Experience

Chief Medical Officer / Medical Director Roles

- MBQ Pharma, Edison Oncology, Seneca Therapeutics, Temple Therapeutics
  - Led clinical development, regulatory strategy, and investor engagement
  - Conducted scientific advisory boards, KOL interactions, and global fundraising

Senior Clinical & Medical Leadership Roles

- Companies: NCI, Medimmune, Otsuka, Genentech, Pharmacyclics, FivePrime, Loxo Oncology, Portola, Rhizen Pharma, Boston Biomedical, Indapta, Strand Pharma, GV20 Therapeutics, Effector Therapeutics, Salarius
  - Clinical trial design, CSR/safety narrative writing, CRF development
  - Regulatory interactions with FDA (including Pre-NDA meetings)
  - Global medical monitoring and drug development strategy
  - CMO advisory and due diligence for licensing and investment deals

# Dr. Neil Sankar, MD, MPH

*Medical Oncologist | C-Suite Executive | Drug Development Leader*

Email: neilshankar@gmail.com Location: United States

## Therapeutic Expertise

Primary Areas: Oncology (solid & hematologic), Immunology, Infectious Diseases

Indications Covered: NHL, CLL, SLL, PTCL, CTCL, AML, GBM, Desmoid Tumors, Ewing's Sarcoma, Sarcomas, Multiple Sclerosis (NK therapy), and various solid tumors

## Technologies and Modalities Worked On

Cell & Gene Therapy: CAR-T, CER-T, NK cell therapy

Immuno-Oncology & Biologics: mAbs, fusion proteins, cytokines

Targeted Therapies: Small molecules, kinase inhibitors, ADCs

Novel Platforms: Oncolytic viruses, mRNA-based therapies

## Notable Accomplishments

Successfully contributed to two NDA filings:

- Kadcyla (ado-trastuzumab emtansine) for Metastatic Breast Cancer
- Ibrutinib for Mantle Cell Lymphoma

Global experience in clinical development across academic, government, and industry sectors

Active involvement in scientific advisory boards, road shows, and clinical fundraising efforts

## Professional Affiliations

American Association for Cancer Research (AACR)

Society for Immunotherapy of Cancer (SITC)

American Society of Clinical Oncology (ASCO)

European Hematology Association (EHA)

American Society of Hematology (ASH)

European Society for Medical Oncology (ESMO)

Connective Tissue Oncology Society (CTOS)